Advancing Breakthrough Therapies Through Strategic Partnerships
From Dawn of Dreams to Dawn of Discoveries.
Collaborating with innovators, healthcare providers, and advocacy groups to accelerate the delivery of transformative RNA and gene therapies
Who We Are
Dawn Therapeutics is a UK-based biotechnology company founded in November 2019, born from scientific and clinical leadership committed to solving some of the most challenging neurological and skeletal diseases. (UK company registration: November 2019) We are dedicated to creating precision delivery platforms for genetic medicines to reach the brain and bone, and translating them toward clinical readiness.
Our Mission
To enable safe, effective, and accessible genetic therapies by building targeted delivery systems that overcome biological barriers. We aim to address rare genetic disorders, neurological conditions with high unmet need, and opportunities to enhance existing treatments through precise targeting.
Our Vision
To transform the lives of patients and families affected by CNS disorders, lysosomal storage diseases, and musculoskeletal conditions through scientific innovation, ethical responsibility, and global collaboration.
Our Core Focuses
- Lead Indication — MPS-I H (Hurler syndrome): Our flagship programme, DAWN-01, is an in vivo lentiviral vector designed to deliver the IDUA gene to both central nervous system and skeletal tissues. This is our most advanced asset and serves as the proof concept for our dual-delivery strategy.
- Deliberate Strategic Expansion: After validating our core concept in MPS-I H, we will extend our delivery platforms to additional rare genetic, neurological, and musculoskeletal diseases—especially those lacking effective therapies.
- Platform-enabled Therapeutic Improvement: Beyond de novo therapy development, we aim to harness our precise delivery technology to improve existing therapeutics—making them safer, more effective, and less toxic by confining action to the target tissue.
Our Expertise
Dawn Therapeutics brings together leaders from:
- Gene Therapy & RNA Therapeutics Development
- Neurology, Genetics, and Musculoskeletal Research
- Regulatory Affairs & Clinical Trial Management
- Manufacturing & Commercialisation
Our proprietary delivery technologies are designed for brain, bone, cartilage, and muscle targeting, unlocking treatment potential in diseases previously considered untreatable.
Our Story
Founded with the vision to bridge the gap between cutting-edge science and patient impact, Dawn Therapeutics emerged from a team of scientists, clinicians, and entrepreneurs united by a shared goal — making targeted genetic therapies a reality for the people who need them most.
Our Delivery and Development Platforms
Dawn Therapeutics is a preclinical, platform-led company focused on solving the delivery bottleneck in genetic medicines. Our approach combines a lead rare disease programme with reusable delivery platforms designed for CNS, joint, cartilage, and other hard-to-target tissues.
DTX-101 Stealth Lentiviral Platform
Our lead programme is built on a third-generation stealth lentiviral vector designed for direct in vivo delivery, with immune-evasion features and a built-in safety switch architecture to support controlled expression in preclinical development.
CNS-Targeting iLNP Delivery
Dawn’s immunologically targeted lipid nanoparticle platform is engineered for precision delivery to the central nervous system, including blood-brain barrier targeting strategies to improve exposure in difficult tissues.
Joint and Cartilage Targeting
A dedicated tissue-targeting approach supports delivery into joints and cartilage, enabling programme expansion into musculoskeletal indications where conventional delivery systems have limited penetration.
Payload Flexibility Across Modalities
The platform strategy is built to support multiple payload types, including DNA and RNA-based systems, with scope for broader gene-editing and oligonucleotide applications in future preclinical programmes.
Promoter and Construct Engineering
Dawn is building protectable know-how around promoter architecture, expression control, and delivery construct optimisation to improve tissue selectivity, durability, and translational performance.
CMC and Translational Execution Platform
Development is supported by a partner-enabled execution model spanning GMP manufacturing, toxicology, CMC strategy, and regulatory planning, designed to move DAWN-01 and follow-on programmes through milestone-gated preclinical development.
Guiding Principles and Development Philosophy
Dawn’s strategy is built around disciplined preclinical execution, partner-enabled delivery, and platform scalability. These principles shape how we prioritise programmes, generate evidence, and engage with investors and partners.
Preclinical Discipline
We use milestone-based work packages and formal Go/No-Go decision points to keep development focused, measurable, and capital efficient.
Translational Evidence First
We prioritise evidence that matters for translation, including tissue targeting, biomarker response, dose strategy, and repeat dosing considerations.
Rare Disease Anchor, Platform Expansion
DAWN-01 provides a focused lead programme while the broader delivery platforms create a path to additional CNS and musculoskeletal programmes.
Partner-Enabled Execution
We combine internal scientific leadership with specialist external partners for manufacturing, toxicology, and regulatory planning to accelerate progress.
Confidentiality with Controlled Disclosure
We share the right level of technical and IP information at the right stage, using a structured diligence process and NDA-based access where needed.
Responsible Development Standards
We are committed to scientific integrity, clear preclinical communication, and a development path that supports responsible partnering and future clinical readiness.
Programme Development Roadmap
Dawn’s roadmap is structured around a lead programme, a partner-enabled execution plan, and milestone-gated preclinical progression.
1. Lead programme focus: DAWN-01 (MPS1H)
Advance the rare disease lead programme with preclinical evidence generation and delivery optimisation.
2. Platform optimisation and tissue targeting
Refine vector and iLNP delivery performance for CNS and joint/cartilage targeting applications.
3. GMP manufacturing planning and process readiness
Execute manufacturing transfer and batch strategy through specialist GMP partners as part of the CMC plan.
4. Toxicology and non-clinical package buildout
Progress dose-ranging and repeat-dose workstreams to support a robust preclinical data package.
5. Regulatory and CMC alignment
Advance target product profile, CMC gap analysis, and regulatory planning through staged external support.
6. Pipeline expansion using shared platforms
Extend into additional liver, CNS, and musculoskeletal indications using the same core delivery technologies.
Scientific Team and Partner Network
Dawn combines internal scientific leadership with a specialist external network to execute preclinical development efficiently across manufacturing, toxicology, and regulatory workstreams.
Commitment to Partners and Diligence Readiness
Our model is designed for serious collaboration. We maintain a structured approach to technical review, data sharing, and confidentiality so strategic partners and investors can assess programmes with confidence.
Dawn welcomes discussions with investors, biopharma partners, and translational collaborators aligned with our preclinical platform and programme strategy.
Request a Discussion